914P - Impact of the addition of rituximab in overall survival in first line chemotherapy in follicular lymphoma: a population-based study from the Spanis...

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Anticancer Agents
Biological Therapy
Presenter Maria Torrente
Citation Annals of Oncology (2016) 27 (6): 313-327. 10.1093/annonc/mdw375
Authors M. Torrente1, P. Sabin2, J. Gomez Codina3, L. de la Cruz Merino4, M. Llanos5, J. Guma I Padro6, C. Quero7, A. Blasco8, F.R. Garcia Arroyo9, A. Rueda10
  • 1Medical Oncology, Hospital Universitario Puerta de Hierro, 28222 - Madrid/ES
  • 2Medical Oncology, Hospital General Universitario Gregorio Marañon, Madrid/ES
  • 3Medical Oncology, Hospital Universitari i Politècnic La Fe, 46026 - Valencia/ES
  • 4Medical Oncology, Hospital Universitario Virgen Macarena, Sevilla/ES
  • 5Medical Oncology, Hospital Universitario de Canarias, santa cruz de tenerife/ES
  • 6Medical Oncology, University Hospital St. Joan de Reus, Reus/ES
  • 7Medical Oncology, Hospital Universitario Virgen de la Victoria, Malaga/ES
  • 8Medical Oncology, Hospital General Universitario Valencia, Valencia/ES
  • 9Medical Oncology, Complejo Hospitalario de Pontevedra, Pontevedra/ES
  • 10Medical Oncology, Hospital Costa del Sol, 29602 - Malaga/ES



The optimal treatment of follicular lymphoma (FL) is not well established. There is no doubt that the clinical development of rituximab (R) has been a significant breakthrough in FL. However, its effect on overall survival (OS) in these patients is still open to debate.


We reviewed 1076 patients treated in our country diagnosed with FL. They were included in the Follicular Lymphoma Registry, a prospective registry within GOTEĹs (Spanish Lymphoma Study Group) database that includes all new lymphoma cases, regardless of their histological subtype, diagnosed in the hospitals within the Group between January 1st 1999, and January 1st 2009. Data were obtained from 16 sites. The median follow up was 54.9 months (0.13-663.12) for the entire series.


The addition of R to the chemotherapy regimen was significantly associated with a superior OS (p  60 years of age (p = 0.05); ECOG > 1 (p = 0.002); Stage III-IV (p = 0.004); more nodal and extranodal involvement (p = 0.003); > LDH (p = 0.007); and higher FLIPI (p = 0.02). Nevertheless, patients with a high-risk disease, according to the FLIPI benefited the most from the addition of R whereas statistical significance was not reached for patients with a low/intermediate FLIPI score.


In our experience, R is associated with better overall survival, especially in patients with high risk FLIPI.

Clinical trial identification

Legal entity responsible for the study

Hospital Universitario Puerta de Hierro


Spanish Lymphoma Oncology Group (GOTEL)


All authors have declared no conflicts of interest.